SITE013-0135

SITE013 (USA) › SITE013-0135

SITE013-0135

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2026-02-13

enrolled

AEs

3

Serious

1

Dropout signal

–

Adverse events

3

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-11 (study day 119); relationship: NOT RELATED

moderate assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 95); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 56); relationship: RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.